Convergence of lipid homeostasis through liver X and thyroid hormone receptors

Mechanisms of Ageing and Development

Volumn 125, Issue 10-11 SPEC. ISS., 2004, Pages 707-717

  Berkenstam, Anders ^a   Färnegårdh, Mathias ^a   Gustafsson, Jan Åke ^b  

^a Karo Bio   (Sweden)

^b KAROLINSKA INSTITUTE   (Sweden)

Author keywords

Atherosclerosis; Dyslipidemia; Liver X receptor; Nuclear receptor; Thyroid hormone receptor

Indexed keywords

CELL NUCLEUS RECEPTOR; ESTROGEN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HORMONE RECEPTOR AFFECTING AGENT; LIVER X RECEPTOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; STEROID HORMONE; THYROID HORMONE RECEPTOR; THYROID HORMONE RECEPTOR AFFECTING AGENT; TRIACYLGLYCEROL; UNCLASSIFIED DRUG;

ATHEROSCLEROSIS; BINDING SITE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; DRUG TARGETING; DYSLIPIDEMIA; HOMEOSTASIS; HUMAN; LIPID METABOLISM; NONHUMAN; PRIORITY JOURNAL; PROTEIN DNA BINDING; PROTEIN DOMAIN; PROTEIN FUNCTION; PROTEIN STRUCTURE; REGULATORY MECHANISM; REVIEW; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 8444222359     PISSN: 00476374     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mad.2004.05.005     Document Type: Article

References (87)

1. J.S. Annicotte, K. Schoonjans, and J. Auwerx Expression of the liver X receptor alpha and beta in embryonic and adult mice Anat. Rec. 277A 2004 312 316
2. S. Alberti, G. Schuster, P. Parini, D. Feltkamp, U. Diczfalusy, M. Rudling, B. Angelin, I. Bjorkhem, S. Pettersson, and J.-Å. Gustafsson Hepatic cholesterol metabolism and resistance to dietary cholesterol in LXRbeta-deficient mice J. Clin. Invest. 107 2001 565 573
3. K.D. Baker, L.M. Shewchuk, T. Kozlova, M. Makishima, A. Hassell, B. Wisely, J.A. Caravella, M.H. Lambert, J.L. Reinking, H. Krause, C.S. Thummel, T.M. Willson, and D.J. Mangelsdorf The Drosophila orphan nuclear receptor DHR38 mediates an atypical ecdysteroid signaling pathway Cell 113 2003 731 742
4. M.E. Baker Evolution of adrenal and sex steroid action in vertebrates: a ligand-based mechanism for complexity Bioessays 25 2003 396 400
5. Barkhem, T., 2002. Molecular mechanism of estrogen and antiestrogen action. Ph.D. Thesis Karolinska Institute, Stockhol, Sweden.
6. S. Borngraeber, M.J. Budny, G. Chiellini, S.T. Cunha-Lima, M. Togashi, P. Webb, J.D. Baxter, T.S. Scanlan, and R.J. Fletterick Ligand selectivity by seeking hydrophobicity in thyroid hormone receptor Proc. Natl. Acad. Sci. USA 100 2003 15358 15363
7. A.R. Cappola, and P.W. Ladenson Hypothyroidism and atherosclerosis J. Clin. Endocrinol. Metab. 88 2003 2438 2444
8. T. Claudel, M.D. Leibowitz, C. Fievet, A. Tailleux, B. Wagner, J.J. Repa, G. Torpier, J.M. Lobaccaro, J.R. Paterniti, D.J. Mangelsdorf, R.A. Heyman, and J. Auwerx Reduction of atherosclerosis in apolipoprotein E knockout mice by activation of the retinoid X receptor Proc. Natl. Acad. Sci. USA 98 2001 2610 2615
9. R. Collins, J. Armitage, S. Parish, P. Sleight, R. Peto Heart Protection Study Collaborative Group Effects of cholesterol-lowering with simvastatin on stroke and other major vascular events in 20536 people with cerebrovascular disease or other high-risk conditions Lancet 363 2004 757 767
10. T.N. Collingwood, R. Wagner, C.H. Matthews, R.J. Clifton-Bligh, M. Gurnell, O. Rajanayagam, M. Agostini, R.J. Fletterick, P. Beck-Peccoz, W. Reinhardt, G. Binder, M.B. Ranke, A. Hermus, R.D. Hesch, J. Lazarus, P. Newrick, V. Parfitt, P. Raggatt, F. de Zegher, and V.K. Chatterjee A role for helix 3 of the TRbeta ligand-binding domain in coactivator recruitment identified by characterization of a third cluster of mutations in resistance to thyroid hormone EMBO J. 17 1998 4760 4770
11. M. Crestani, E. De Fabiani, D. Caruso, N. Mitro, F. Gilardi, A.B. Vigil Chacon, R. Patelli, C. Godio, and G. Galli LXR (liver X receptor) and HNF-4 (hepatocyte nuclear factor-4): key regulators in reverse cholesterol transport Biochem. Soc. Trans. 32 2004 92 96
12. M.D. Danese, P.W. Ladenson, C.L. Meinert, and N.R. Powe Clinical review 115: effect of thyroxine therapy on serum lipoproteins in patients with mild thyroid failure: a quantitative review of the literature J. Clin. Endocrinol. Metab. 85 2000 2993 3001
13. Datamonitor, 2003. Pipeline insight: Dyslipidemia. Reference code: DMHC 1885.
14. B. Desvergne How do thyroid hormone receptors bind to structurally diverse response elements? Mol. Cell Endocrinol. 100 1994 125 131
15. M.J. Diekman, N. Anghelescu, E. Endert, O. Bakker, and W.M. Wiersinga Changes in plasma low-density lipoprotein (LDL)- and high-density lipoprotein cholesterol in hypo- and hyperthyroid patients are related to changes in free thyroxine, not to polymorphisms in LDL receptor or cholesterol ester transfer protein genes J. Clin. Endocrinol. Metab. 85 2000 1857 1862
16. V.A. Drover, and L.B. Agellon Regulation of the human cholesterol 7alpha hydroxylase gene (CYP7A1) by thyroid hormone in transgenic mice Endocrinology 145 2004 574 581
17. H. Duez, Y.S. Chao, M. Hernandez, G. Torpier, P. Poulain, S. Mundt, Z. Mallat, E. Teissier, C.A. Burton, A. Tedgui, J.C. Fruchart, C. Fievet, S.D. Wright, and B. Staels Reduction of atherosclerosis by the peroxisome proliferator-activated receptor alpha agonist fenofibrate in mice J. Biol. Chem. 277 2002 48051 48057
18. L.H. Duntas Thyroid disease and lipids Thyroid 12 2002 287 293
19. P.A. Edwards, M.A. Kennedy, and P.A. Mak LXRs; oxysterol-activated nuclear receptors that regulate genes controlling lipid homeostasis Vascul. Pharmacol. 38 2002 249 256
20. E. Enmark, and J.-Å. Gustafsson Comparing nuclear receptors in worms, flies and humans Trends Pharmacol. Sci. 22 2001 611 615
21. M. Farnegardh, T. Bonn, S. Sun, J. Ljunggren, H. Ahola, A. Wilhelmsson, J.-Å. Gustafsson, and M. Carlquist The three-dimensional structure of the liver X receptor beta reveals a flexible ligand-binding pocket that can accommodate fundamentally different ligands J. Biol. Chem. 278 2003 38821 38828
22. F. Flamant, and J. Samarut Thyroid hormone receptors: lessons from knockout and knock-in mutant mice Trends Endocrinol. Metab. 14 2003 85 90
23. A. Flores-Morales, H. Gullberg, L. Fernandez, N. Stahlberg, N.H. Lee, B. Vennstrom, and G. Norstedt Patterns of liver gene expression governed by TRbeta Mol. Endocrinol. 16 2002 1257 1268
24. E.S. Ford, W.H. Giles, and W.H. Dietz Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey JAMA 287 2002 356 359
25. P.A. Greenidge, B. Carlsson, L.G. Bladh, and M. Gillner Pharmacophores incorporating numerous excluded volumes defined by X-ray crystallographic structure in three-dimensional database searching: application to the thyroid hormone receptor J. Med. Chem. 41 1998 2503 2512
26. P. Greenland, M.D. Knoll, J. Stamler, J.D. Neaton, A.R. Dyer, D.B. Garside, and P.W. Wilson Major risk factors as antecedents of fatal and nonfatal coronary heart disease events JAMA 290 2003 891 897
27. A. Grefhorst, B.M. Elzinga, P.J. Voshol, T. Plosch, T. Kok, V.W. Bloks, F.H. van der Sluijs, L.M. Havekes, J.A. Romijn, H.J. Verkade, and F. Kuipers Stimulation of lipogenesis by pharmacological activation of the liver X receptor leads to production of large, triglyceride-rich very low density lipoprotein particles J. Biol. Chem. 277 2002 34182 34190
28. H. Grøn, and R. Hyde-DeRuyscher Peptides as tools in drug discovery Curr. Opin. Drug Discov. Dev. 3 2000 636 645
29. H. Gronemeyer, and D. Moras Nuclear receptors. How to finger DNA Nature 375 1995 190 191
30. G.J. Grover, K. Mellstrom, L. Ye, J. Malm, Y.L. Li, L.G. Bladh, P.G. Sleph, M.A. Smith, R. George, B. Vennstrom, K. Mookhtiar, R. Horvath, J. Speelman, D. Egan, and J.D. Baxter Selective thyroid hormone receptor-beta activation: a strategy for reduction of weight, cholesterol, and lipoprotein (a) with reduced cardiovascular liability Proc. Natl. Acad. Sci. USA 100 2003 10067 10072
31. G.J. Grover, D.M. Egan, P.G. Sleph, B.C. Beehler, G. Chiellini, N.H. Nguyen, J.D. Baxter, and T.S. Scanlan Effects of the thyroid hormone receptor agonist GC-1 on metabolic rate and cholesterol in rats and primates: selective actions relative to 3,5,3′-triiodo-L-thyronine Endocrinology 145 2004 1656 1661
32. H. Gullberg, M. Rudling, C. Salto, D. Forrest, B. Angelin, and B. Vennstrom Requirement for thyroid hormone receptor beta in T3 regulation of cholesterol metabolism in mice Mol. Endocrinol. 16 2002 1767 1777
33. J.J. Hangeland, A.M. Doweyko, T. Dejneka, T.J. Friends, P. Devasthale, K. Mellstrom, J. Sandberg, M. Grynfarb, J.S. Sack, H. Einspahr, M. Farnegardh, B. Husman, J. Ljunggren, K. Koehler, C. Sheppard, J. Malm, and D.E. Ryono Thyroid receptor ligands. Part 2: Thyromimetics with improved selectivity for the thyroid hormone receptor beta Bioorg. Med. Chem. Lett. 14 2004 3549 3553
34. S. Hoerer, A. Schmid, A. Heckel, R.M. Budzinski, and H. Nar Crystal structure of the human liver X receptor beta ligand-binding domain in complex with a synthetic agonist J. Mol. Biol. 334 2003 853 861
35. X. Hu, S. Li, J. Wu, C. Xia, and D.S. Lala Liver X receptors interact with corepressors to regulate gene expression Mol. Endocrinol. 17 2003 1019 1026
36. Iannone MA, Simmons CA, Kadwell, SH, Svoboda DL, Vanderwall DE, Deng S-J, Consler TG, Shearin J, Gray JG, Pearce KH. 2004. Correlation between in vitro peptide binding profiles and cellular activities for estrogen receptor modulating compounds. Mol. Endocrinol. 2003-0432.
37. S.B. Joseph, and P. Tontonoz LXRs: new therapeutic targets in atherosclerosis? Curr. Opin. Pharmacol. 3 2003 192 197
38. S.B. Joseph, E. McKilligin, L. Pei, M.A. Watson, A.R. Collins, B.A. Laffitte, M. Chen, G. Noh, J. Goodman, G.N. Hagger, J. Tran, T.K. Tippin, X. Wang, A.J. Lusis, W.A. Hsueh, R.E. Law, J.L. Collins, T.M. Willson, and P. Tontonoz Synthetic LXR ligand inhibits the development of atherosclerosis in mice Proc. Natl. Acad. Sci. USA 99 2002 7604 7609
39. B. Kauppi, C. Jakob, M. Farnegardh, J. Yang, H. Ahola, M. Alarcon, K. Calles, O. Engstrom, J. Harlan, S. Muchmore, A.K. Ramqvist, S. Thorell, L. Ohman, J. Greer, J.-Å. Gustafsson, J. Carlstedt-Duke, and M. Carlquist The three-dimensional structures of antagonistic and agonistic forms of the glucocorticoid receptor ligand-binding domain: RU-486 induces a transconformation that leads to active antagonism J. Biol. Chem. 278 2003 22748 22754
40. U.N. Khot, M.B. Khot, C.T. Bajzer, S.K. Sapp, E.M. Ohman, S.J. Brener, S.G. Ellis, A.M. Lincoff, and E.J. Topol Prevalence of conventional risk factors in patients with coronary heart disease JAMA 290 2003 898 904
41. V. Laudet, and H. Gronemeyer The Nuclear Receptor Facts Book 2002 Academic Press
42. M.A. Lazar Thyroid hormone action: a binding contract J. Clin. Invest. 112 2003 497 509
43. Y. Li, M.H. Lambert, and H.E. Xu Activation of nuclear receptors: a perspective from structural genomics Structure 11 2003 741 746
44. Y. Li, C. Bolten, B.G. Bhat, J. Woodring-Dietz, S. Li, S.K. Prayaga, C. Xia, and D.S. Lala Induction of human liver X receptor alpha gene expression via an autoregulatory loop mechanism Mol. Endocrinol. 16 2002 506 514
45. Z. Levi, A. Shaish, N. Yacov, H. Levkovitz, S. Trestman, Y. Gerber, H. Cohen, A. Dvir, R. Rhachmani, M. Ravid, and D. Harats Rosiglitazone (PPARgamma-agonist) attenuates atherogenesis with no effect on hyperglycaemia in a combined diabetes-atherosclerosis mouse model Diabetes Obes. Metab. 5 2003 45 50
46. E.G. Lund, J.G. Menke, and C.P. Sparrow Liver X receptor agonists as potential therapeutic agents for dyslipidemia and atherosclerosis Arterioscler. Thromb. Vasc. Biol. 23 2003 1169 1177
47. R.M. Mason, H.M. Hunt, and L. Hurxthal Blood cholesterol values in hyperthyroidism and hypothyroidism N. Engl. J. Med. 203 1930 1273 1278
48. K.N. Maxwell, R.E. Soccio, E.M. Duncan, E. Sehayek, and J.L. Breslow Novel putative SREBP and LXR target genes identified by microarray analysis in liver of cholesterol-fed mice J. Lipid. Res. 44 2003 2109 2119
49. N.J. McKenna, and B.W. O'Malley Minireview: nuclear receptor coactivators-an update Endocrinology 143 2002 2461 2465
50. J.M. McKenney, P.H. Jones, M.A. Adamczyk, V.A. Cain, B.S. Bryzinski, J.W. Blasetto STELLAR Study Group Comparison of the efficacy of rosuvastatin versus atorvastatin, simvastatin, and pravastatin in achieving lipid goals: results from the STELLAR trial Curr. Med. Res. Opin. 19 2003 689 698
51. J.G. Menke, K.L. Macnaul, N.S. Hayes, J. Baffic, Y.S. Chao, A. Elbrecht, L.J. Kelly, M.H. Lam, A. Schmidt, S. Sahoo, J. Wang, S.D. Wright, P. Xin, G. Zhou, D.E. Moller, and C.P. Sparrow A novel liver X receptor agonist establishes species differences in the regulation of cholesterol 7alpha-hydroxylase (CYP7a) Endocrinology 143 2002 2548 2558
52. R. Mohan, and R.A. Heyman Orphan nuclear receptor modulators Curr. Top. Med. Chem. 3 2003 1637 1647
53. D.R. Nelson Cytochrome P450 and the individuality of species Arch. Biochem. Biophys. 369 1999 1 10
54. T. Ostberg, G. Bertilsson, L. Jendeberg, A. Berkenstam, and J. Uppenberg Identification of residues in the PXR ligand binding domain critical for species specific and constitutive activation Eur. J. Biochem. 269 2002 4896 4904
55. L.A. Paige, D.J. Christensen, H. Grøn, J.D. Norris, E.B. Gottlin, K.M. Padilla, C.Y. Chang, L.M. Ballas, P.T. Hamilton, D.P. McDonnell, and D.M. Fowlkes Estrogen receptor (ER) modulators each induce distinct conformational changes in ER alpha and ER beta Proc. Natl. Acad. Sci. USA 96 1999 3999 4004
56. T.A. Pearson, I. Laurora, H. Chu, and S. Kafonek The lipid treatment assessment project (L-TAP): a multicenter survey to evaluate the percentages of dyslipidemic patients receiving lipid-lowering therapy and achieving low-density lipoprotein cholesterol goals Arch. Intern. Med. 160 2000 459 467
57. D.J. Peet, S.D. Turley, W. Ma, B.A. Janowski, J.M. Lobaccaro, R.E. Hammer, and D.J. Mangelsdorf Cholesterol and bile acid metabolism are impaired in mice lacking the nuclear oxysterol receptor LXR alpha Cell 93 1998 693 704
58. F. Rastinejad, T. Perlmann, R.M. Evans, and P.B. Sigler Structural determinants of nuclear receptor assembly on DNA direct repeats Nature 375 1995 203 211
59. R.N. Redinger Nuclear receptors in cholesterol catabolism: molecular biology of the enterohepatic circulation of bile salts and its role in cholesterol homeostasis J. Lab. Clin. Med. 142 2003 7 20
60. J.J. Repa, G. Liang, J. Ou, Y. Bashmakov, J.M. Lobaccaro, I. Shimomura, B. Shan, M.S. Brown, J.L. Goldstein, and D.J. Mangelsdorf Regulation of mouse sterol regulatory element-binding protein-1c gene (SREBP-1c) by oxysterol receptors, LXRalpha and LXRbeta Genes Dev. 14 2000 2819 2830
61. C.G. Roberts, and P.W. Ladenson Hypothyroidism Lancet 363 2004 793 803
62. Ruau, D., Duarte, J., Ourjdal, T., Perriere, G., Laudet, V., Robinson-Rechavi, M., 2004. Update of NUREBASE: nuclear hormone receptor functional genomics. Nucleic Acids Res. 32 Database issue: D165-7. http://www.ens-lyon.fr/LBMC/laudet/nurebase/nurebase.html.
63. J.W. Schwabe, and S.A. Teichmann Nuclear receptors: the evolution of diversity Sci. STKE 217 2004 pe4
64. N. Shibusawa, A.N. Hollenberg, and F.E. Wondisford Thyroid hormone receptor DNA binding is required for both positive and negative gene regulation J. Biol. Chem. 278 2003 732 738
65. K.R. Steffensen, and J.-Å. Gustafsson Putative metabolic effects of the liver X receptor (LXR) Diabetes 53 Suppl. 1 2004 S36 S42
66. M. Schapira, B.M. Raaka, S. Das, L. Fan, M. Totrov, Z. Zhou, S.R. Wilson, R. Abagyan, and H.H. Samuels Discovery of diverse thyroid hormone receptor antagonists by high-throughput docking Proc. Natl. Acad. Sci. USA 100 2003 7354 7359
67. P.L. Shaffer, and D.T. Gewirth Structural basis of VDR-DNA interactions on direct repeat response elements EMBO J. 21 2002 2242 2252
68. P.L. Shaffer, A. Jivan, D.E. Dollins, F. Claessens, and D.T. Gewirth Structural basis of androgen receptor binding to selective androgen response elements Proc. Natl. Acad. Sci. USA 101 2004 4758 4763
69. D.J. Shin, and T.F. Osborne Thyroid hormone regulation and cholesterol metabolism are connected through Sterol Regulatory Element-Binding Protein-2 (SREBP-2) J. Biol. Chem. 278 2003 34114 34118
70. E. Shimoji, B. Zhang, P. Fan, and K. Saku Inhibition of cholesteryl ester transfer protein increases serum apolipoprotein (apo) A-I levels by increasing the synthesis of apo A-I in rabbits Atherosclerosis 172 2004 247 257
71. C. Song, and S. Liao Cholestenoic acid is a naturally occurring ligand for liver X receptor alpha Endocrinology 141 2000 4180 4184
72. C. Song, R.A. Hiipakka, and S. Liao Selective activation of liver X receptor alpha by 6alpha-hydroxy bile acids and analogs Steroids 65 2000 423 437
73. S. Svensson, T. Ostberg, M. Jacobsson, C. Norstrom, K. Stefansson, D. Hallen, I.C. Johansson, K. Zachrisson, D. Ogg, and L. Jendeberg Crystal structure of the heterodimeric complex of LXRalpha and RXRbeta ligand-binding domains in a fully agonistic conformation EMBO J. 22 2003 4625 4633
74. R.K. Tangirala, E.D. Bischoff, S.B. Joseph, B.L. Wagner, R. Walczak, B.A. Laffitte, C.L. Daige, D. Thomas, R.A. Heyman, D.J. Mangelsdorf, X. Wang, A.J. Lusis, P. Tontonoz, and I.G. Schulman Identification of macrophage liver X receptors as inhibitors of atherosclerosis Proc. Natl. Acad. Sci. USA 99 2002 11896 11901
75. J.W. Thornton, E. Need, and D. Crews Resurrecting the ancestral steroid receptor: ancient origin of estrogen signaling Science 301 2003 1714 1717
76. J.W. Thornton Evolution of vertebrate steroid receptors from an ancestral estrogen receptor by ligand exploitation and serial genome expansions Proc. Natl. Acad. Sci. USA 98 2001 5671 5676
77. P. Tontonoz, and D.J. Mangelsdorf Liver X receptor signaling pathways in cardiovascular disease Mol. Endocrinol. 17 2003 985 993
78. J. Uppenberg, C. Svensson, M. Jaki, G. Bertilsson, L. Jendeberg, and A. Berkenstam Crystal structure of the ligand binding domain of the human nuclear receptor PPARgamma J. Biol. Chem. 273 1998 31108 31112
79. M. Wang, and M.R. Briggs HDL: the metabolism, function, and therapeutic importance Chem. Rev. 104 2004 119 137
80. Z. Wang, G. Benoit, J. Liu, S. Prasad, P. Aarnisalo, X. Liu, H. Xu, N.P. Walker, and T. Perlmann Structure and function of Nurr1 identifies a class of ligand-independent nuclear receptors Nature 423 2003 555 560
81. R.L. Wagner, J.W. Apriletti, M.E. McGrath, B.L. West, J.D. Baxter, and R.J. Fletterick A structural role for hormone in the thyroid hormone receptor Nature 378 1995 690 697
82. S. Williams, R.K. Bledsoe, J.L. Collins, S. Boggs, M.H. Lambert, A.B. Miller, J. Moore, D.D. McKee, L. Moore, J. Nichols, D. Parks, M. Watson, B. Wisely, and T.M. Willson X-ray crystal structure of the liver X receptor beta ligand binding domain:regulation by a histidine-tryptophan switch J. Biol. Chem. 278 2003 27138 27143
83. T.M. Willson, P.J. Brown, D.D. Sternbach, and B.R. Henke The PPARs: from orphan receptors to drug discovery J. Med. Chem. 43 2000 527 550
84. H.A. Yoshihara, N.H. Nguyen, and T.S. Scanlan Design and synthesis of receptor ligands Methods Enzymol. 364 2003 71 91
85. B. Zandieh-Doulabi, E. Dop, M. Schneiders, M.P. Schiphorst, A. Mansen, B. Vennstrom, C.D. Dijkstra, O. Bakker, and W.M. Wiersinga Zonal expression of the thyroid hormone receptor alpha isoforms in rodent liver J. Endocrinol. 179 2003 379 385
86. J. Zhang, and M.A. Lazar The mechanism of action of thyroid hormones Annu. Rev. Physiol. 62 2000 439 466
87. Y. Zhang, L. Yin, and F.B. Hillgartner SREBP-1 integrates the actions of thyroid hormone, insulin, cAMP, and medium-chain fatty acids on ACCalpha transcription in hepatocytes J. Lipid. Res. 44 2003 356 368